Skip to content

Fostering Diversity & Inclusion: Embracing Differences at Scailyte

Highlighting Our Commitment to Diversity & Inclusion

A Diverse and Inclusive Team: Celebrating Differences at Scailyte

Highlighting Our Commitment to Diversity and Inclusion

🌍 At Scailyte, we take great pride in our commitment to Environmental, Social, and Governance (ESG) principles. Today, we want to highlight our strong focus on Diversity and Inclusion, particularly in terms of nationality and gender pay. 🌈🤝

With a team of 22 people, we have fostered a diverse and inclusive environment where everyone’s unique backgrounds and perspectives are celebrated. We firmly believe that diversity fuels innovation and drives success. 💡🚀

Gender diversity is a top priority for us, and we are proud to say that 50% of our full team consists of talented and inspiring women. But it doesn’t stop there—when it comes to leadership positions, 2 of the 3 C-level positions are held by exceptional women. 💼👩‍💼

Our diversity extends beyond gender. We are a team comprised of individuals from various nationalities, representing the rich tapestry of cultures around the globe. 🌎✨ Here is a snapshot of the nationalities that make up our Scailyte family:

🇧🇬 Bulgaria

🇨🇭 Switzerland

🇺🇸 USA

🇫🇷 France

🇮🇹 Italy

🇵🇹 Portugal

🇵🇱 Poland

🇩🇪 Germany

🇵🇰 Pakistan

🇮🇳 India

🇧🇩 Bangladesh

🏴󠁧󠁢󠁷󠁬󠁳󠁿 Wales

🇳🇿 New Zealand

🇭🇷 Croatia

By embracing such a diverse range of backgrounds, experiences, and perspectives, we foster an inclusive environment that values and respects everyone’s contributions. Together, we push the boundaries of innovation and create groundbreaking solutions for the future. 💪💫

At Scailyte, we firmly believe that true success is achieved through the collective power of a diverse and inclusive workforce. We remain committed to nurturing a culture that promotes equality, fosters innovation, and empowers every individual to thrive. 🌟🤝

 

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. 

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Precision Medicine and The Future of Genomics Summit 2024

Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...

Read more

Recent News

Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution

In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...

Read more

Recent News

Pitch Nic 2024 at Novartis Campus

We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...

Read more

Recent News

Genomics for Health 2024

Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...

Read more

Recent News

The Year of the AI Nobel

2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...

Read more

Recent News

Life Science Industry Meets Data Science Symposium

Scailyte is thrilled to be part of the LIFE SCIENCE INDUSTRY MEETS DATA SCIENCE symposium organised ...

Read more

Recent News

World CB & CDx Summit 2024

Scailyte is thrilled to attend Hanson Wade's 14th World CB & CDx Summit - the flagship CDx event of ...

Read more

Recent News

01 /04

Precision Medicine and The Future of Genomics Summit 2024

Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...

Read more

Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution

In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...

Read more

Recent News

02 /04

Pitch Nic 2024 at Novartis Campus

We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...

Read more

Recent News

03 /04

Genomics for Health 2024

Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...

Read more

The Year of the AI Nobel

2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...

Read more

Recent News

04 /04

Life Science Industry Meets Data Science Symposium

Scailyte is thrilled to be part of the LIFE SCIENCE INDUSTRY MEETS DATA SCIENCE symposium organised ...

Read more

World CB & CDx Summit 2024

Scailyte is thrilled to attend Hanson Wade's 14th World CB & CDx Summit - the flagship CDx event of ...

Read more

Recent News